Therefore, the present study evaluates the possible association between response to ICIs and mRNA levels of TGF-β, IFN-γ and PD-L1 in circulating EVs isolated from peripheral blood of patients with metastatic melanoma treated with first-line nivolumab or pembrolizumab; radiomic features are also investigated in a subset of patients. The gene discussed is TGFB1; the disease is metastatic melanoma.